Avenue de JouquesSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

Validation Lab Laboratory Road 128, Intersection 376 Yauco, 00698 Puerto RicoSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

Road 128, Intersection 368 Bo Susua Boja, Susua Industrial Park Yauco, Puerto Rico, 00698 United StatesSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

Groner sie Kanger 1 Goettingen, 37081 GermanySartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

Zone Industrielle Les Paluds Auenue de Jouques- CS 91051 Aubagne, 13781 FranceSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

1 Technology Terrace, Todd Campus West of Scotland Science Park Glasgow, Lanarkshire, G20 0XA United KingdomSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.

89 Avenue du Parc Industriel Herstal, Région wallonne, 4041 BelgiumSartorius Xpress Biologics, a Belgian subsidiary of Sartorius, proposes contract services for the process development and manufacturing of recombinant proteins, including antibody fragments, and plasmid DNA for research, preclinical and clinical applications specific to the human & veterinary therapeutic, vaccine and diagnostic markets. Sartorius Xpress Biologics specializes in the development of microbial manufacturing processes using E. coli to produce recombinant proteins and plasmid DNA and P. pastoris to produce recombinant proteins. Both, the production scale, from 100 mg up to several tens of grams, and the manufacturing grades of the biologics (Research, GLP/HQ and GMP grades) proposed by Sartorius Xpress Biologics are adapted for in vitro and in vivo research applications, preclinical validation (proof-of-concept, early safety, potency, efficacy, toxicity…) and clinical validation of the biologics. Sartorius Xpress Biologics processes are free of charge in terms of license or royalty fees. The services proposed by Sartorius Xpress Biologics are based on 4 technological platforms:  molecular biology for the design of microbial expression systems (E. coli & P. pastoris),  fermentation development with 5L fermenters for production yield optimization and scale-up development and production with 15 and 50L fermenters,  downstream process development including extraction, clarification, liquid chromatography, tangential flow filtration…,  quality control (HPLC, spectrophotometry…). The company offers the following services:  design and development of microbial expression strains,  development of the UspStream Process (USP) including fermentation and protein/DNA extraction,  development of the DownStream Process (DSP) including purification and formulation,  realization of stress studies and formulation development,  development of analytical tools,  realization of long-term stability studies,  process scale-up study,  biologics manufacturing.